Agomab General Counsel reports stock option holdings

Q: What does the Agomab Therapeutics (AGMB) Form 3 for Ellen Lefever report?

The Form 3 reports initial beneficial ownership of several stock option awards over Agomab common shares. It lists each grant’s exercise price, expiration date, vesting status, and that the options are held directly by the General Counsel.

Q: How many Agomab (AGMB) shares are covered by Ellen Lefever’s key stock options?

The filing shows stock options covering multiple blocks of common shares, including 91,256 underlying shares at $2.7600 expiring in 2031 and 127,972 underlying shares at $14.2600 expiring in 2036, among other grants.

Q: What are the exercise prices of the stock options reported by Agomab’s General Counsel?

The options have exercise prices of $2.7600, $3.1800 and $14.2600 per common share. Footnotes state these prices are reported in U.S. dollars, converted from euros using a specified EUR/USD exchange rate as of March 16, 2026.

Q: When do Ellen Lefever’s reported Agomab (AGMB) stock options expire?

The reported stock options expire between March 5, 2031 and January 15, 2036. Each grant lists a specific expiration date, showing the long-dated nature of these awards and the time window during which they may be exercised.

Q: Are the Agomab stock options held by Ellen Lefever vested according to the Form 3?

One option grant is described as fully vested and exercisable. Other grants vest over time, including schedules where 50% vests on February 9, 2026 or 25% on February 9, 2027, with remaining portions vesting in equal monthly installments subject to continued service.

Q: Can Agomab (AGMB) common shares from these options be held as ADSs?

Yes. A footnote states that common shares may be represented by American Depositary Shares, with each ADS currently representing one common share. This means option exercises could ultimately result in either directly held shares or ADSs on a 1:1 basis.

Agomab Therapeutics NV General Counsel Ellen Lefever filed an initial statement of beneficial ownership, detailing several stock option awards over common shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Agomab Therapeutics NV General Counsel Ellen Lefever filed an initial statement of beneficial ownership, detailing several stock option awards over common shares. These options give rights to buy AGMB shares at exercise prices including $2.7600, $3.1800 and $14.2600, with expirations from 2031 through 2036.

One grant covers 91,256 underlying common shares at $2.7600 per share expiring on March 5, 2031, and another covers 127,972 shares at $14.2600 expiring on January 15, 2036, all held directly. Footnotes note that some options are fully vested while others vest over time, that common shares may be represented by ADSs on a 1:1 basis, and that exercise prices are reported in U.S. dollars using a stated EUR/USD exchange rate.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Lefever Ellen

Role General Counsel

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 457,304 contracts (Direct)

Footnotes (5)

F1. The shares underlying this option are fully vested and exercisable.
F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
F4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Agomab Therapeutics (AGMB) Form 3 for Ellen Lefever report?

The Form 3 reports initial beneficial ownership of several stock option awards over Agomab common shares. It lists each grant’s exercise price, expiration date, vesting status, and that the options are held directly by the General Counsel.

How many Agomab (AGMB) shares are covered by Ellen Lefever’s key stock options?

The filing shows stock options covering multiple blocks of common shares, including 91,256 underlying shares at $2.7600 expiring in 2031 and 127,972 underlying shares at $14.2600 expiring in 2036, among other grants.

What are the exercise prices of the stock options reported by Agomab’s General Counsel?

The options have exercise prices of $2.7600, $3.1800 and $14.2600 per common share. Footnotes state these prices are reported in U.S. dollars, converted from euros using a specified EUR/USD exchange rate as of March 16, 2026.

When do Ellen Lefever’s reported Agomab (AGMB) stock options expire?

The reported stock options expire between March 5, 2031 and January 15, 2036. Each grant lists a specific expiration date, showing the long-dated nature of these awards and the time window during which they may be exercised.

Are the Agomab stock options held by Ellen Lefever vested according to the Form 3?

One option grant is described as fully vested and exercisable. Other grants vest over time, including schedules where 50% vests on February 9, 2026 or 25% on February 9, 2027, with remaining portions vesting in equal monthly installments subject to continued service.

Can Agomab (AGMB) common shares from these options be held as ADSs?

Yes. A footnote states that common shares may be represented by American Depositary Shares, with each ADS currently representing one common share. This means option exercises could ultimately result in either directly held shares or ADSs on a 1:1 basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lefever Ellen

(Last)

(First)

(Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN

2600

(City)

(State)

(Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	03/05/2031	Common shares⁽²⁾	91,256	$2.76⁽³⁾	D
Stock Option (Right to Buy)	⁽¹⁾	06/28/2032	Common shares⁽²⁾	48,009	$2.76⁽³⁾	D
Stock Option (Right to Buy)	⁽¹⁾	10/10/2033	Common shares⁽²⁾	54,113	$2.76⁽³⁾	D
Stock Option (Right to Buy)	⁽⁴⁾	07/08/2034	Common shares⁽²⁾	3,832	$2.76⁽³⁾	D
Stock Option (Right to Buy)	⁽⁴⁾	11/04/2034	Common shares⁽²⁾	132,122	$3.18⁽³⁾	D
Stock Option (Right to Buy)	⁽⁵⁾	01/15/2036	Common shares⁽²⁾	127,972	$14.26⁽³⁾	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

Agomab General Counsel reports stock option holdings

Rhea-AI Filing Summary

Positive

Negative